Harmony Biosciences Holdings, Inc. (HRMY) Research

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

Market snapshot

Symbol
HRMY
Price
$33.28
Day change
-1.45%
Market cap
$1.9B
P/E ratio
13.21x
52-week range
25.52-40.87
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$43.00

Peer companies

  • AbCellera Biologics Inc. (ABCL)
  • Aurinia Pharmaceuticals Inc. (AUPH)
  • Biohaven Ltd. (BHVN)
  • Celldex Therapeutics, Inc. (CLDX)
  • Immunocore Holdings plc (IMCR)
  • Janux Therapeutics, Inc. (JANX)
  • MannKind Corporation (MNKD)
  • Nuvation Bio Inc. (NUVB)

Recent insider activity

  • Germano Geno J — A-Award (21231 shares) on 2026-05-14
  • Germano Geno J — trade (0 shares) on 2026-05-14
  • Szyper Linda M — A-Award (21872 shares) on 2026-05-14
  • Philip Ron M — A-Award (21872 shares) on 2026-05-14
  • Graf R. Mark — A-Award (21872 shares) on 2026-05-14

Open Harmony Biosciences Holdings, Inc. (HRMY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.